Lōvu Health

Here is a fact that ought to be more embarrassing than it is: the United States has one of the highest maternal mortality rates in the wealthy world, and most of those deaths are considered preventable. The clinical villains are not exotic. They are preeclampsia, chronic hypertension, and perinatal depression - conditions with warning signs that show up as ordinary numbers. Blood pressure. Weight. Fetal heart rate. A mood questionnaire. The problem is that a pregnant woman sees her obstetrician for something like fifteen minutes a month, and the rest of the time those numbers accumulate quietly at home, unread.

Lōvu Health, founded in 2022 and headquartered in Cupertino, is built around a fairly unglamorous observation: the data that predicts a maternal crisis mostly already exists. It is just trapped between appointments. So Lōvu ships the mother a connected kit - a blood pressure monitor, a smart scale, a fetal Doppler - and streams the readings to a clinician dashboard in real time. An AI layer watches for drift. When something looks wrong, a human pregnancy navigator, assigned to each mother, coordinates with her OB. The pitch is not "replace the doctor." It is "stop making the doctor wait a month to see the trend line."

The company's own numbers are the interesting part, because they are less about the technology and more about what the technology found. On its platform, Lōvu says it identified preeclampsia earlier in 6% of mothers, detected depression or anxiety in more than 30% of its population, and surfaced chronic hypertension in 57% of the mothers who had it. That last figure is the one worth sitting with. More than half of the affected mothers were carrying a serious, manageable risk factor that the platform is the one that flagged. That is not a story about a slick app. It is a story about a market that assumed a known problem was already being handled, and discovered it wasn't.

Lōvu's second insight is architectural. Rather than build fifty specialty services - doula support, lactation consulting, pelvic floor physical therapy, genetic testing coordination, mental health care - it built one marketplace and let more than fifty third-party vendors plug into it. In a fragmented market, the company that wins is rarely the best individual provider. It is the one that makes all the other providers reachable at the right moment, without the mother assembling a scavenger hunt of apps and portals. Lōvu positions itself as the operating system underneath the whole journey, from pre-conception through two years postpartum.

There is a deliberate restraint in how the product meets the clinician. Lōvu integrates into the OB's existing workflow with, in the company's telling, no new software and no new logins. If you have ever tried to sell software into a hospital, you understand why that sentence is the entire go-to-market strategy. The fastest path into a clinic is the one that adds nothing to anyone's plate. You hand the doctor better data, sooner, and you ask them to change nothing about how they already work.

The founding pair fits the thesis. Noel Pugh, the co-founder and CEO, is a healthcare economist by training - he holds both a PhD and a JD - with prior time at HCA Healthcare, Mednax, PatientPing and Medneon. He knows, in a structural way, why the system leaks. His co-founder, Dr. Santosh Pandipati, is a maternal-fetal medicine physician and serves as Chief Health Officer; he knows what the leak feels like at 3 a.m. in labor and delivery. One diagnoses the system, the other diagnoses the patient. Complementary founders are not a nicety in healthcare. They are most of the moat.

In September 2025 the company raised an $8 million Series A led by SJF Ventures, with a notably women's-fund-heavy syndicate - Rogue Women's Fund, Symphonic Capital, Emmeline Ventures, Majella Ventures, Oakwood Circle Ventures, Sand Hill Angels, Swizzle Ventures, Terrasys, Stand Together Ventures and Alumni Ventures. That brings total funding to roughly $14 million. The money is earmarked for three AI agents, more automation, deeper system integrations and hiring. A month later, Lōvu paired with Tenovi to launch a cellular-connected RPM kit - a cuff, a scale, a fetal Doppler and a gateway that sends data without home WiFi. The choice of cellular is not incidental. The mothers most likely to die in childbirth are frequently the ones with the worst connectivity, in rural and underserved communities. The hardest customers to reach tend to be the ones who need you most.

Whether Lōvu becomes maternity care's data layer or one of several credible contenders - alongside the Maven Clinics and Babyscripts and Delfinas of the femtech world - is unsettled. What is clear is the shape of the bet. Not a moonshot device. Not a chatbot that plays doctor. Just a stubborn insistence that if a mother is already taking her blood pressure at home, somebody clinical should be looking at it before it becomes an emergency.